<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ketoprofen</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01009</strong>&#160; (APRD01059, DB05823)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (<span class="caps">NSAIA</span>) with analgesic and antipyretic properties.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01009/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01009/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01009.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01009.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01009.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01009.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01009.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01009">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-(3-Benzoylphenyl)propionic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>3-Benzoyl-&#945;-methylbenzeneacetic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>3-Benzoylhydratropic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>m-Benzoylhydratropic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Actron</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Alrheumun</td><td>Teofarma</td></tr><tr><td>Capisten</td><td>Kissei</td></tr><tr><td>Epatec</td><td>Zeria Shinyaku</td></tr><tr><td>Fastum</td><td>Menarini</td></tr><tr><td>Menamin</td><td>Daiko Seiyaku</td></tr><tr><td>Orudis</td><td>Abbott</td></tr><tr><td>Orudis KT</td><td>Sanofi</td></tr><tr><td>Orugesic</td><td>Sanofi</td></tr><tr><td>Oruvail</td><td>Wyeth</td></tr><tr><td>Oscorel</td><td>Sanofi</td></tr><tr><td>Profenid</td><td>Sanofi</td></tr><tr><td>Toprec</td><td>Sanofi</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li>
<li><a href="/mesh/cyclooxygenase-inhibitors">Cyclooxygenase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>22071-15-4</td></tr><tr><th>Weight</th><td>Average: 254.2806<br>Monoisotopic: 254.094294314</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>14</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>DKYWVDODHFEZIM-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(3-benzoylphenyl)propanoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzophenones</td></tr><tr><th>Direct parent</th><td>Benzophenones</td></tr><tr><th>Alternative parents</th><td>Diphenylmethanes; Phenylpropanoic Acids; Phenylacetic Acid Derivatives; Acetophenones; Benzoyl Derivatives; Ketones; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>2-phenylpropanoic-acid; phenylacetate; acetophenone; benzoyl; ketone; carboxylic acid derivative; carboxylic acid; enolate; polyamine; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.</td></tr><tr><th>Pharmacodynamics</th><td>Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.</td></tr><tr><th>Mechanism of action</th><td>The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. </td></tr><tr><th>Absorption</th><td>Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>99% bound, primarily to albumin</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Ketoprofen</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00589">Ketoprofen glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/607">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.</td></tr><tr><th>Half life</th><td>Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p></td></tr><tr><th>Clearance</th><td><ul>
	<li>Oral-dose cl=6.9 +/-  0.8 L/h [Ketoprofen Immediate-release capsules (4 &#215; 50 mg)]</li>
	<li>Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 &#215; 200 mg)]</li>
	<li>0.08 L/kg/h</li>
	<li>0.7 L/kg/h [alcoholic cirrhosis patients]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=62.4 mg/kg (rat, oral). 
<p>Symptoms of overdose include drowsiness, vomiting and abdominal pain.</p>
<p>Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.</p></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Ketoprofen Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9928</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7132</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9168</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9589</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8818</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7183</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9598</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7685</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9604</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9465</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9598</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9438</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9801
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6299
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.6701
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2378 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9661
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9595
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Elan pharmaceutical research corp</li>
<li>Mylan pharmaceuticals inc</li>
<li>Watson laboratories inc florida</li>
<li>Wyeth pharmaceuticals inc</li>
<li>Heritage pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Wyeth ayerst laboratories</li>
<li>Novartis consumer health inc</li>
<li>Bayer healthcare llc</li>
<li>L perrigo co</li>
<li>Wyeth consumer healthcare</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aidarex.com">Aidarex Pharmacuticals LLC</a></li>
<li>Apothecary Shop Wholesale</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.elan.com">Elan Pharmaceuticals Inc.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li><a href="http://www.letcomedical.com">Letco Medical Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmapacllc.com">Pharma Pac LLC</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prescription Dispensing Service Inc.</li>
<li>Professional Co.</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>100 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>50 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>75 mg</td></tr><tr><td>Capsule, extended release</td><td>Oral</td><td>200 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The NSAID, ketoprofen, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended. </td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The NSAID, ketoprofen, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The NSAID, ketoprofen, may increase the serum concentration of cyclosporine. Ketoprofen may also increase the nephrotoxicity of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The NSAID, ketoprofen, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00055">Drotrecogin alfa</a></td><td>The antiplatelet effect of ketoprofen may increase the bleed risk associated with drotrecogin alfa. Consider spacing use of the two agents by at least 7 days. Increase monitoring for signs and symptoms of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Ketoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. </td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.</td></tr><tr><td><a href="/drugs/DB01404">Ginseng</a></td><td>Increased risk of bleeding due to additive anticoagulant properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.</td></tr><tr><td><a href="/drugs/DB00465">Ketorolac</a></td><td>Concomitant use of ketoprofen and ketorolac, two NSAIDs, is contraindicated due to the risk of additive or synergistic NSAID toxicities (e.g. GI bleeding, ulceration, renal dysfunction, etc).  </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The NSAID, ketoprofen, may increase the serum concentration of lithium by decreasing its renal clearance. Consider a dose reduction in lithium upon initiation of ketoprofen therapy. Monitor for changes in the therapeutic and adverse effects of lithium if ketoprofen is initiated, discontinued or does changed. </td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The NSAID, ketoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00642">Pemetrexed</a></td><td>The NSAID, ketoprofen, may increase increase the serum concentration of pemetrexed by decreasing its renal clearance. Patients with mild to moderate renal insufficiency (CrCl 45-79 ml/min) should avoid use of ketoprofen within 2 days of a pemetrexed dose. Patients with better renal function do not appear to be at risk. Monitor for toxicity in all patients during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00118">S-Adenosylmethionine</a></td><td>Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Concomitant use of Telmisartan and Ketoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. </td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>The NSAID, Ketoprofen, may antagonize the antihypertensive effect of Timolol.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The NSAID, Ketoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketoprofen is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketoprofen. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Food prolongs rate of absorption and decreases peak plasma concentration. Extent of absorption is not affected. </li>
<li>Take with food to reduce gastric irritation.</li></ul></td></tr></tbody></table>